162 related articles for article (PubMed ID: 24995304)
1. Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma.
Valković T; Babarović E; Lučin K; Štifter S; Aralica M; Pećanić S; Seili-Bekafigo I; Duletić-Načinović A; Nemet D; Jonjić N
Biomed Res Int; 2014; 2014():513170. PubMed ID: 24995304
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Prognostic Performance of Serum Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor 2, and Osteopontin for Gastrointestinal Cancers.
Jiang L; Hochwald S; Deng S; Chen Y; Tan C; Zhong Q; Huang H
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775874
[TBL] [Abstract][Full Text] [Related]
3. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Ostheimer C; Bache M; Güttler A; Kotzsch M; Vordermark D
Strahlenther Onkol; 2014 Mar; 190(3):276-82. PubMed ID: 24322994
[TBL] [Abstract][Full Text] [Related]
4. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of bone sialoprotein, osteopontin, and β2-microglobulin in stage I of multiple myeloma.
Maaroufi A; Khadem-Ansari MH; Khalkhali HR; Rasmi Y
J Cancer Res Ther; 2020; 16(1):98-101. PubMed ID: 32362616
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9.
Kerenidi T; Kazakou AP; Lada M; Tsilioni I; Daniil Z; Gourgoulianis KI
Cancer Invest; 2016 Sep; 34(8):385-92. PubMed ID: 27624849
[TBL] [Abstract][Full Text] [Related]
7. OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma.
Treskova I; Topolcan O; Windrichova J; Simanek V; Slouka D; Treska V; Kucera R
Anticancer Res; 2018 Aug; 38(8):4907-4911. PubMed ID: 30061268
[TBL] [Abstract][Full Text] [Related]
8. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma.
Sfiridaki A; Miyakis S; Pappa C; Tsirakis G; Alegakis A; Kotsis V; Stathopoulos E; Alexandrakis M
J Hematol Oncol; 2011 May; 4():22. PubMed ID: 21548993
[TBL] [Abstract][Full Text] [Related]
9. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications.
Saeki Y; Mima T; Ishii T; Ogata A; Kobayashi H; Ohshima S; Ishida T; Tabunoki Y; Kitayama H; Mizuki M; Katada Y; Asaoku H; Kitano M; Nishimoto N; Yoshizaki K; Maeda M; Kon S; Kinoshita N; Uede T; Kawase I
Br J Haematol; 2003 Oct; 123(2):263-70. PubMed ID: 14531907
[TBL] [Abstract][Full Text] [Related]
10. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
[TBL] [Abstract][Full Text] [Related]
13. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
15. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
[TBL] [Abstract][Full Text] [Related]
16. [Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma].
Usnarska-Zubkiewicz L; Mazur G; Wróbel T; Poreba M; Kuliczkowski K
Pol Arch Med Wewn; 2003 Jul; 110(1):719-24. PubMed ID: 14682206
[TBL] [Abstract][Full Text] [Related]
17. Tumor load in patients with multiple myeloma: β₂-microglobulin levels versus low-dose whole-body CT.
Pfahler V; D'Anastasi M; Dürr HR; Schinner R; Ricke J; Baur-Melnyk A
Eur J Haematol; 2020 May; 104(5):383-389. PubMed ID: 31762076
[TBL] [Abstract][Full Text] [Related]
18. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin And Angiogenic Factors As New Biomarkers Of Prostate Cancer.
Wisniewski T; Zyromska A; Makarewicz R; Zekanowska E
Urol J; 2019 May; 16(2):134-140. PubMed ID: 30178447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
